Treatment of quiescent NIH3T3 cells with PDGF BB results in the transient activation and hyperphosphorylation of the protein-tyrosine kinase, c-Src. These eects correlate with novel serine and tyrosine phosphorylations in the N-terminal non-catalytic region of the molecule, which contains an SH3 and SH2 domain. In this study, a site of PDGF-induced tyrosine phosphorylation was mapped to Tyr 138 in the SH3 domain; Tyr 138 is exposed on the SH3 peptide binding surface. This same site is phosphorylated in vitro by the PDGF receptor when puri®ed baculovirus-expressed c-Src is complexed with the activated receptor. Phosphorylation of Tyr 138 required association of c-Src with the PDGF receptor via its SH2 domain. When a c-Src Phe 138 mutant was stably expressed in Src 7 mouse ®broblasts, it was activated to the same extent as wild type c-Src following PDGF stimulation, indicating that phosphorylation of this site is not required for PDGF-mediated activation. However, Tyr 138 phosphorylation was found to diminish SH3 domain peptide ligand binding ability in vitro.
Introduction
The proto-oncogene product, pp60 c-src , is a membraneanchored nonreceptor protein-tyrosine kinase (PTK) with N-terminal SH3 and SH2 domains originally identi®ed in a mutated form as the transforming protein pp60
v-src of Rous sarcoma virus (Collett et al., 1980; Sefton et al., 1980) . It is the founding member of the Src family of PTKs which includes c-Yes, Fyn, cFgr, Lck, Lyn, Hck, Blk and Yrk (Mustelin, 1994) . All members are *500 ± 550 amino acids long with three conserved domains (SH3, SH2 and catalytic), and a unique N-terminal domain. Just C-terminal to the catalytic domain, a negative regulatory phosphorylation site, Tyr 527, is also a conserved feature in the Src PTK family. c-Src is activated *2-fold during mitosis (Shenoy et al., 1989) , by association with polyoma mT antigen (Courtneidge, 1985) , and following plateletderived growth factor (PDGF) treatment of quiescent mouse ®broblasts (Gould and Hunter, 1988; Ralston and Bishop, 1985) . PDGF-stimulated c-Src activation was previously correlated with tyrosine and serine phosphorylation in the N-terminal half of c-Src (Gould and Hunter, 1988; Ralston and Bishop, 1985) . A novel phosphotyrosine-and two phosphoserine-containing peptides were identi®ed in the N-terminal half (Gould and Hunter, 1988) , but the sites of tyrosine and serine phosphorylation had not been identi®ed, nor was it known if these phosphorylations played a role in c-Src activation.
c-Src, Fyn and c-Yes are widely expressed in vertebrates, whereas other Src family members are expressed in a more restricted fashion, in some cases being limited to a discrete hematopoietic lineage. The phenotype of mice lacking c-Src is surprisingly normal , although they develop postnatal osteopetrosis, a bone remodeling defect, due to an osteoclast de®ciency (Lowe et al., 1993) . Mice lacking Fyn or c-Yes also display relatively normal phenotypes (Appleby et al., 1992; Grant et al., 1992; Stein et al., 1992 Stein et al., , 1994 . Thus, there appears to be some degree of functional redundancy between widely expressed Src family members, such as Fyn and c-Yes. Consistent with this, mice lacking both Fyn and c-Src or c-Yes and c-Src die shortly after birth and mice lacking Fyn and c-Yes develop renal disease .
The SH2 and SH3 domains of Src, which confer protein-protein interactions, are also found in many other unrelated eector molecules. Both domains are compact and modular. Proteins with SH2 and SH3 domains have been divided into two groups: those with enzymatic activities are called SH2/SH3 enzymes, and those without are called SH2/SH3 adaptors (Pawson and Gish, 1992) . Structures of both domains have been solved from a variety of SH2/SH3 enzymes and adaptors including c-Src (Booker et al., 1992; Overduin et al., 1992; Waksman et al., 1992) . The biochemical function of the SH2 domain is to bind to a phosphotyrosine (PTyr) residue found in a speci®c sequence context, while the function of the SH3 domain is to bind to short (510 amino acids) proline-rich motifs with a Pro.X.X.Pro core.
Some proposed physiological roles for SH3 and SH2 domains include bringing signal transducing PTKs and substrates into proximity with each other (Koch et al., 1991 (Koch et al., , 1992 and translocation to the plasma membrane. PDGF receptor protein-tyrosine kinase (RPTK) ligand binding induces receptor dimerization and transautophosphorylation of tyrosines that bind SH2 eector molecules, such as Grb2, GAP, Nck, PI3 kinase, SHP2 and PLCg, leading to the activation of a variety of mitogenic signaling pathways, including the Ras-ERK MAP kinase pathway (van der Geer et al., 1994) . Another role for SH2 and SH3 domains is evident in the negative regulation of Src family kinase activity. Both domains are required for stable binding of the SH2 domain to phosphorylated Tyr 527 leading to an intramolecular interaction that represses catalytic activity (Liu et al., 1993a; Murphy et al., 1993; Okada et al., 1993; Superti-Furga et al., 1993) .
The Src family PTKs play a role in signal transduction by several dierent types of cell surface receptor (Mustelin, 1994; van der Geer et al., 1994) . For instance, Src family PTKs are required for signaling in the vertebrate immune system via antigen and Fc receptors, which lack intrinsic enzymatic activity (for review see Mustelin, 1994) . T cell stimulation, which results in cytokine production and proliferation, is correlated with Src family activation. Lck associates with the T cell surface molecules CD4 and CD8 and is activated upon crosslinking. Fyn associates with the T cell antigen receptor CD3 z chain and is activated upon antigen binding. Lyn, Lck and Blk associate with the B cell receptor and are involved in antigen signaling. Fyn, Lck, and Lyn associate functionally with subunits of various Fc receptors. The Src family PTKs have also been shown to be involved in signaling via IL-2 and IL-7 cytokine receptors, which also lack enzymatic activity. (Taniguchi, 1995) .
Src family PTKs are also required for signaling via RPTKs. Like c-Src, the Src family members Fyn and cYes, are activated and become hyperphosphorylated following PDGF treatment of quiescent ®broblasts (Kypta et al., 1990) . More signi®cantly, all three associate with the activated PDGF receptor and form a stable complex. About 5% of the PDGF receptor and Src family PTK populations associate, and PDGF treatment causes a phosphorylation-dependent shift of *5% of Src molecules on one and two-dimensional gels (Gould and Hunter, 1988) . c-Src binding to the PDGF receptor is direct and is mediated by the c-Src SH2 domain (Twamley et al., 1992) . PDGF receptorassociated kinase-inactive Fyn was tyrosine phosphorylated on the N-terminal half at an unidenti®ed site, implying that Fyn is phosphorylated by the PDGF receptor rather than by autophosphorylation. Binding of CSF-1 to the CSF-1 receptor, an RPTK in the PDGF receptor family, also leads to Src family PTK association and activation . The c-Src binding site on the human PDGFb receptor has been identi®ed as PTyr 579/PTyr 581 located in the juxtamembrane region of the activated receptor dimer (Mori et al., 1993) . Although c-Src only binds weakly to the activated EGF receptor in vitro (Luttrell et al., 1994; Stover et al., 1995) , phosphorylation of the EGF receptor by c-Src in vitro at sites not autophosphorylated by the receptor creates a binding site for the c-Src SH2 domain (Stover et al., 1995) and c-Src association with the EGF receptor can be detected by coimmunoprecipitation following EGF treatment of some cell lines (Stover et al., 1995) . A requirement for Src family PTKs in PDGF, EGF and CSF-1-induced mitogenesis has been demonstrated by microinjection of antibodies against the common C-terminal sequence of c-Src, Fyn and c-Yes or of plasmids expressing kinase-inactive forms of c-Src and Fyn (Roche et al., 1995; Twamley-Stein et al., 1993) . Thus, it appears that Src family PTKs are important components of RPTK mitogenic signal transduction, but the signal pathways activated by the Src family PTKs downstream of the receptors are unknown.
In this study, we have identi®ed Tyr 138 as a site of c-Src N-terminal tyrosine phosphorylation induced by PDGF, and showed that Tyr 138 is phosphorylated directly by the PDGF receptor in vitro. No eect of mutating Tyr 138 to phenylalanine on PDGF-induced c-Src activation was observed when a Y138F c-Src mutant was expressed in a Src 7 mouse ®broblast cell line. However, we found that phosphorylation of Tyr 138 diminished c-Src SH3 peptide ligand binding ability in vitro.
Results
A peptide containing the phosphorylated N-terminal tyrosine in c-Src from PDGF-treated NIH3T3 cells was originally detected by sequential digestion of V8 protease generated fragments of Src containing the N-terminal 20 kDa of the protein with trypsin and (Gould and Hunter, 1988) . To identify this site of tyrosine phosphorylation we took both in vivo and in vitro approaches. Initially, we made the assumption that this side would be phosphorylated directly by the PDGF receptor. Preliminary experiments showed that the N-terminal portions of c-Src, contained in GST-SH3 and GST-SH2 fusion proteins, failed to act as substrates for the PDGF receptor in vitro (data not shown). In contrast, synthetic peptides corresponding to the predicted N-terminal c-Src fragments released by trypsin and thermolysin digestion that contain the ®ve potential N-terminal tyrosine phosphorylation sites (see Figure 1) were readily phosphorylated by the receptor in vitro. However, despite repeated attempts to show comigration of these phosphorylated synthetic peptides with the PDGFinduced PTyr-containing tryptic-thermolytic c-Src peptide, none of them comigrated. It should be noted that Tyr 133 and Tyr 138 both failed to act as phosphorylation sites in these synthetic peptide phosphorylation experiments, while Tyr 92, Tyr 94 and Tyr 151 were all good sites (data not shown). Therefore, we decided to test whether puri®ed full length c-Src would be an appropriate substrate. For this purpose we devised a protocol for expressing and purifying wild type mouse c-Src and various mutant forms in a baculovirus expression system.
Expression and puri®cation of c-Src from insect cells
To obtain puri®ed c-Src proteins for the in vitro studies we initially tried immunoanity puri®cation of c-Src from recombinant baculovirus infected Spodoptera frugiperda (Sf9) insect cells (BEVS). Following a procedure developed by Morgan et al. (1991) , the anti-Src monoclonal antibody (MAb) 327 (Lipsich et al., 1983) was immobilized on a solid support resin and used to isolate c-Src proteins from recombinant baculovirus-infected Sf9 whole cell lysates (Morgan et al., 1991) . However, preliminary characterization of the immunoanity puri®ed Src proteins indicated that there were at least two drawbacks to using this procedure to isolate recombinant c-Src from insect cells. The ®rst was its inability to discriminate between myristoylated, properly modi®ed recombinant c-Src proteins localized to infected insect cell membranes and unmodi®ed, denatured recombinant c-Src found in both soluble and insoluble states in these cells. Several groups have noted that 50% or more of baculovirusexpressed Src protein is not myristoylated (Gartner et al., 1992; Piwnica-Worms et al., 1990; Ramer et al., 1991) . The second drawback is the requirement for using pH 11 buer to elute c-Src from the column, which inevitably causes some denaturation. A major concern in these studies was that any denaturation might prevent in vitro replication of the observed in vivo PDGF-induced phosphorylation. Despite this concern, DI296T c-Src, an N-terminal fragment of cSrc consisting of the ®rst 298 residues, was immunoaf®nity puri®ed for mapping purposes and successfully used for biochemical studies on the eects of Tyr 138 phosphorylation on c-Src SH3 function in vitro.
To avoid these drawbacks, a native puri®cation scheme was developed to yield recombinant c-Src proteins that are of higher quality than those isolated by immunoanity (Table 1) . A key advance in this approach was the application of poly Glu-Tyr (E 4 Y 1 ) and poly Glu-Ala-Tyr (E 6 A 3 Y 1 ) anity resins ®rst described by Racker and colleagues in a related c-Src puri®cation procedure developed for both baculovirusexpressed c-Src and for isolation of Src family PTKs from primary vertebrate tissues (Zhang et al., 1991) . The major changes to this procedure are the use of infected insect cell membrane preparations instead of whole cell lysates, and inclusion of an ion exchange resin, Fast Q (Pharmacia), as a step prior to the E 4 Y 1 and E 6 A 3 Y 1 anity resin steps, which allows the repeated use of the E 4 Y 1 anity resin without signi®cant degradation of the resin caused by passing whole cell extracts over it.
The recovery and puri®cation of recombinant c-Src from baculovirus infected insect cells using the native puri®cation scheme is shown in Table 1 . The overall yield from 5610 7 (2.3 g) infected Sf9 cells was *60 mg or 30% of the total activity ± note that the activity was measured using Mg 2+ as the divalent cation cofactor and not the preferred Mn 2+ due to technical reasons involving the buer conditions used (phosphate-buered solutions cause precipitation of Mn 2+ -ATP complexes in the kinase assay). Also, there is an apparent activation following the Fast Q ion-exchange step, possibly due to the removal of inhibitory proteins or protein-tyrosine phosphatases (PTPs). Therefore, ®nal recoveries and yields are better determined relative to the activity measured following the Fast Q step. Finally, the fold puri®cation obtained after the E 6 A 3 Y 1 anity step is not signi®cantly better than it is after the E 4 Y 1 step. The yield, however, is considerably less after the E 6 A 3 Y 1 step. Therefore, the majority of kinase-inactive c-Src PDGF receptor substrates used in this mapping study were puri®ed using only the E 4 Y 1 anity step.
Identi®cation of the c-Src N-terminal in vitro PDGF receptor tyrosine phosphorylation site: use of puri®ed baculovirus-produced Src proteins
To test whether intact c-Src would act as a substrate for the PDGF receptor, native puri®ed kinase-inactive K297M mutant c-Src was bound to baculovirusexpressed, immune-complexed, mouse PDGFb receptor, which had been activated by incubation with ATP. Following binding of c-Src the complexes were washed and incubated with [g 32 P]ATP, and the samples were resolved by SDS ± PAGE (Figure 2 ). The K297M c-Src protein was phosphorylated and comigrated with autophosphorylated c-Src. One-dimensional mapping P  u  r  i  f  i  c  a  t  i  o  n  o  f  c  -S  r  c  p  r  o  t  e  i  n  -t  y  r  o  s  i  n  e  k  i  n  a  s  e  a  c  t  i  v  i  t  y  f  r  o  m   r  e  c  o  m  b  i  n  a  n  t  b  a  c  u  l  o  v  i  r  u  s  -i  n  f  e  c  t  e  d  i  n  s  e  c  t  S  f  9  c  e  l  l  s   T  o  t  a  l  S  p  e  c  i  f  i  c  P  r  o  t  e  i  n  a  c  t  i  v The c-Src N-terminal phosphorylation site is contained within the N-terminal V1 fragment, and its derivative V3 and V4 subfragments, which are generated by V8 protease cleavage of c-Src ( Figure  1 ). The V3 subfragment consists of residues 1 ± 180, which contain only ®ve tyrosines, four of which lie within the SH3 domain. To identify which tyrosine is phosphorylated, Tyr 92, 94, 133, 138 and 151 were mutated to phenylalanine individually and in combinations in K297M c-Src. The K297M and K297M Tyr to Phe mutant proteins were expressed in insect cells, puri®ed, phosphorylated after association with the PDGF receptor (Figure 2a) , and subjected to V8 protease mapping in the same way as for wild type cSrc. The V2 fragment was extensively phosphorylated in all the samples, presumably as a result of PDGF receptor phosphorylation of Tyr 418 (data not shown). The site of V2 phosphorylation in these assays has been con®rmed to be Tyr 418 (416 in chicken c-Src), which is the Src autophosphorylation site (data not shown). It appears that the PDGF receptor can transphosphorylate bound c-Src on this residue, since the level of V2 phosphorylation was higher than that obtained with an equivalent amount of K297M c-Src protein alone (data not shown). There is precedence for transphosphorylation between Src and RPTKs, and between kinase-inactive mutant Src and wild type Src in yeast (Cooper and MacAuley, 1988) . RPTKs that have been reported to transphosphorylate c-Src include the INS, IGF-1 and EGF receptors (Kozma and Weber, 1990; Wasilenko et al., 1991; Yu et al., 1985) .
To eliminate the problem with the transphosphorylation of Tyr 418, we expressed the N-terminal 298 amino acids of c-Src in BEVS and puri®ed this protein by MAb 327 immunoanity chromatography. The Nterminal fragment of c-Src, DI296T, consisting of the ®rst 298 residues of c-Src served as a good substrate for in vitro Tyr phosphorylation by the PDGF receptor (Figure 2a ). In the corresponding V8 map the V2 fragment is absent as expected (Figure 2b ). We also analysed the c-Src N-terminal tyrosine mutations by in vitro phosphorylation, using V8 mapping and analysis of the N-terminal V1, V3 and V4 fragments to get Because the sequence surrounding Tyr 138 ( Figure  1c ) has¯anking prolines at positions 73 and +3, we reasoned that potential PTyr 138-containing phosphopeptides ought to be sensitive to proline-speci®c endopeptidase. Two-dimensional phosphopeptide mapping was performed on the 32 P-labeled V1, V3 and V4 fragments using either a combination of trypsin, thermolysin, and proline-speci®c endopeptidase (Figure 3a) ; or endoproteinase Asp-N (V8 protease) and proline-speci®c endopeptidase (Figure 3b ). Although proline-speci®c endopeptidase alone did not cleave the intact V1, V3, and V4 fragments, secondary cleavage using this protease following either trypsin-thermolysin igure 3 Analysis of the DI296T N-terminal c-Src fragment phosphorylated by the PDGF receptor. The DI296T N-terminal c-Src fragment was phosphorylated by the PDGF receptor as described in Figure 2 and subjected to one-dimensional phosphopeptide mapping by Staphylococcus aureus V8 partial proteolysis. The 32 P-labeled V1, V3, and V4 phosphopeptides were excised for further two-dimensional phosphopeptide analysis and manual Edman degradation. (a) 32 P-labeled V1, V3 and V4 N-terminal V8 fragments were excised, eluted, pooled, precipitated, and digested to completion with trypsin. The samples were then digested with thermolysin. Phosphopeptides were solubilized in pH 4.72 electrophoresis buer and spotted onto thin layer cellulose (TLC) plates. The phosphopeptides were resolved in two dimensions: pH 4.72 elecrophoresis (pH 4.72e) horizontally (anode on the left) followed by ascending solvent chromatography in phospho-chromatography (P-Chromo) buer in the second vertical dimension as described in Materials and methods. Dried plates were exposed to ®lm overnight at RT. The major tryptic-thermolytic phosphopeptide (see Figure 5d ) was eluted from the TLC plate; half the sample was treated with proline-speci®c endopeptidase. The digested sample was then loaded onto the left (+) origin of a double origin TLC plate. The undigested control was loaded onto the right (7) origin. Arrowheads indicate the origins. The phosphopeptides were resolved in two dimensions as above. Dried plates were exposed to ®lm overnight at RT. (b) 32 P-labeled V1, V3 and V4 N-terminal V8 fragments were excised, eluted, pooled, precipitated, and digested to completion with endoproteinase Asp-N. Phosphopeptides were solubilized in pH 4.72 electrophoresis buer, spotted on thin layer cellulose (TLC) plates, and the phosphopeptides were resolved in two dimensions as in a. The major phosphopeptides were eluted from the TLC plate; half the sample was treated with proline-speci®c endopeptidase. Subsequent two-dimensional analysis was as described for a. (c) The major phosphopeptides from the triple digest (A) and the double digest (B) were eluted and subjected to three rounds of manual Edman degradation. The upper panel is the triple digest sample, and the lower panel is the double digest sample. Both samples and a reference PTH-PTyr standard, indicated on each panel, were resolved in one dimension by pH 3.5 electrophoresis (pH 3.5e) horizontally (anode on the left). The dried plate was exposed to ®lm overnight at RT Trypsin/Thermolysin P-Chromo + pH 4.72 ε -Endoproteinase Asp-N a b¨P double digestion or Asp-N digestion yielded major phosphopeptides that comigrated (data not shown). Based on the sequence (Figure 1c ) proline endopeptidase digestion of the limit products of the trypsinthermolysin and Asp-N digestion should not yield identical phosphopeptides, but we suspect that the phosphate on Tyr 138 inhibited thermolysin digestion at Val 139 and in this case one would expect-identical products. A second minor species was also detected in the Asp-N/proline-speci®c endopeptidase double digest. We do not know the identity of this peptide, but it appears to be the digestion product of the minor peptide running above and to the left of the major peptide in the endoproteinase Asp-N digest. Manual Edman degradation of the major phosphopeptide obtained by either trypsin, thermolysin, prolinespeci®c endopeptidase triple digestion ( Figure 3c , upper panel) or Asp-N, proline-speci®c endopeptidase double digestion (Figure 3c , lower panel) revealed that PTyr was released in the third cycle consistent with the expected ®nal peptide cleavage product.
Comparison of the two-dimensional tryptic-thermolytic proteolytic phosphopeptide maps of PDGF receptor phosphorylated DI296T c-Src and PDGFinduced in vivo phosphorylated c-Src by comigration revealed that Tyr 138 is the major, if not the exclusive, site of N-terminal tyrosine phosphorylation (see Figure  5d and e).
Identi®cation of Tyr 138 as the c-Src N-terminal in vivo PDGF-induced tyrosine phosphorylation site
The N-terminal Tyr to Phe mutants were also used to identify the PDGF-induced c-Src N-terminal tyrosine phosphorylation site in vivo. This strategy required the use of cells lacking endogenous c-Src, since endogenous wild type c-Src would confuse the results obtained from the mutants. For this purpose, recombinant pNeoMSV (Karn et al., 1989) retroviruses encoding wild type mouse c-Src, Y133F, Y138F, and other Tyr to Phe mutants were used to infect a clone of immortalized mouse ®broblasts derived from mice containing a targeted c-src gene disruption (Src 7 ) . Transiently-expressing pools of wild type, Y133F and Y138F c-Src-infected Src 7 cells were used in the mapping experiments, since initial attempts to produce drug-selected stable cell lines failed. This clone of Src 7 cells is resistant to G418 because both the vector used in the targeted c-src gene disruption and that used to express SV40 large T antigen to immortalize the cells contained the Neo r gene (Brown et al., 1986; Thomas et al., 1991) . Retroviral vectors containing a hygromycin resistance gene were also tried, but these also failed to achieve selectable expression since the sensitivity of these Src 7 cells to hygromycin was too great. By using C2 retrovirus-producing/packaging cell line supernatants containing *10 5 virus particles per ml to infect Src (Broome and Hunter, 1996) and (data not shown).
To analyse PDGF-induced c-Src phosphorylation infected monolayers were serum-starved for 36 ± 40 h to induce quiescence and then labeled metabolically + and V4 + ) were subjected to trypsin and thermolysin double protease digestion as originally described by Gould and Hunter (1988) . Tryptic-thermolytic phosphopeptides were resolved by electrophoresis pH 4.72 (anode on the left) on thinlayer cellulose (TLC) plates, followed by chromatography.
The mapping of the in vivo-labeled c-Src samples con®rmed that Tyr 138 was the PDGF-induced site of in vivo c-Src N-terminal tyrosine phosphorylation. Figure 5c ) lacked any PTyr-containing phosphopeptides, and also lacked any detectable N-terminal PTyr upon phosphoamino acid analysis (PAA) (data not shown). The Y133F mutant c-Src had a PTyr-containing peptide that migrated faster in the chromatography dimension than the PTyr 138 peptide (Figure 5b ). We suggest this peptide contains PTyr 138 and has an altered mobility because Tyr 133 is located in the same trypticthermolytic peptide as Tyr 138 and in this case is mutated to phenylalanine. Mutation of Tyr 133 to Phe would result in a peptide having a more hydrophobic nature than the wild type Tyr 133 peptide (Boyle et al., 1991) , and in consequence the Y133F mutant PTyr 138 peptide should migrate faster in the chromatography dimension. In vivo peptide maps of the Y92/94F and Y151F c-Src mutants both had the PTyr 138 peptide (data not shown).
The positions of the N-terminal Ser 12 and Ser 17 tryptic-thermolytic phosphopeptides are shown in Figure 5a . The other N-terminal c-Src peptides generated by trypsin and thermolysin double digestion have not been identi®ed. One of these peptides presumably represents the novel PDGF-induced Nterminal serine phosphorylation described by Gould and Hunter (1988) . The fact that hyperphosphorylation of the Y138F c-Src mutant is stimulated by PDGF even though Tyr 138 is mutated, is most likely due to the fact that the PDGF-induced Ser phosphorylation is unaected by the Y138F mutation.
We showed that the same tyrosine was phosphorylated by the PDGF receptor in vitro as in vivo by analysing mixtures of digests from in vitro PDGF receptor phosphorylated K297M mutant c-Src and DI296T c-Src N-terminal fragment, with c-Src from PDGF-treated cells (Figure 5e ). In both cases the PTyr 138 phosphopeptides comigrated. Incomplete cleavage of the c-Src N-terminal V8 fragments by trypsin and thermolysin results in some background spots (X, Y and Z) apparent in the DI296T in vitro map (Figure 5d ). There was no evidence for in vitro phosphorylation of other c-Src N-terminal tyrosines in DI296T. When peptides containing Tyr 92, Tyr 94 and Tyr 151 synthesized to mimic either tryptic or trypticthermolytic N-terminal c-Src fragments were phosphorylated in vitro by the PDGF receptor, none of them had mobilities that corresponded to any of the phosphopeptides present in Figure 5d (data not shown). These results taken together con®rm that Tyr 138 is also phosphorylated in vivo following PDGF treatment of quiescent ®broblasts.
Biochemical characterization of the Y138F c-Src phosphorylation site mutant To determine whether Tyr 138 phosphorylation played a role in the activation of c-Src tyrosine kianse catalytic activity following PDGF stimulation, the ability of PDGF to activate Y138F mutant c-Src was examined. Separate pools of Src 7 cells stably expressing wild type mouse c-Src, Y133F mutant c-Src and Y138F phosphorylation site mutant c-Src were generated by selection at high concentrations of G418 (Broome and Hunter, 1996) . The cells were starved of serum, and quiescent monolayers were treated with PDGF BB. c-Src proteins were isolated by immunoprecipitation from cell lysates with the Src-speci®c MAb 2-17, which recognizes the ®rst 17 residues of Src, and does not recognize Fyn or c-Yes. Immune-complex kinase assays were performed using acid-denatured enolase as an exogenous substrate. Immune complexes were divided in two, with one half assayed for activity (Figure 6a) , and the other half blotted to normalize for the amount of c-Src protein in each assay (data not shown). A relative fold increase in c-Src kinase activity was measured, and the average result of three kinase assays is shown in Figure 6b . All three c-Src proteins exhibited approximately 1.5 ± 2-fold activation following PDGF treatment. The results indicate that the inability to phosphorylate Tyr 138 has no eect on cSrc activation following PDGF treatment.
We observed one curious phenomenon, however. Both the c-Src Y133F and Y138F mutants failed to coprecipitate the PDGF receptor from 1% NP40 lysates of PDGF BB treated cells, whereas wild type c-Src consistently did (Figure 6a ). When cells were lysed in RIPA buer, which contains DOC and SDS, even the wild type c-Src/PDGF receptor complex was not detected, either because the interaction is destabilized or because the receptor kinase is inactivated. Nevertheless, the PDGF-induced activation of wild type c-Src was still detectable after isolation from RIPA lysates (data not shown). This result indicates that the PDGF receptor bound to wild type c-Src does not contribute to enolase phosphorylation, which otherwise would be a concern. PDGF activation of Y133F and Y138F c-Src was also detected in RIPA lysates. In summary, there is apparently no essential role for Tyr 138 phosphorylation in the mechanism of c-Src activation by PDGF with the caveat that Phe 138 may not mimic unphosphorylated Tyr 138.
Biochemical analysis of the eects of Tyr 138 phosphorylation on SH3 function Based on the reported structure of the c-Src SH3 domain, the location of Tyr 138 is on the peptide ligand binding surface (Musacchio et al., 1994; Noble et al., 1993; Yu et al., 1992 Yu et al., , 1994 ). This residue is highly conserved in Src family SH3 domains and is highlighted in the Src family SH3 amino acid alignment shown in Figure 7 . Tyr 138 is exposed directly to the surface that interacts with the ligand and has been shown to be a residue that undergoes bond angles changes upon c-Src peptide ligand binding in solution (Yu et al., 1992) . Computer-simulated phosphorylation of Tyr 138 in the wild type c-Src SH3 domain indicated that the phosphate on Tyr 138 would signi®cantly increase the negative electrostatic surface potential in the ligand binding groove, and would be predicted to aect ligand binding (data not shown).
To test whether Tyr 138 phosphorylation aects cSrc SH3 ligand binding function, we used the DI296T N-terminal 298 residue c-Src fragment. We chose DI296T c-Src because it was phosphorylated by the PDGF receptor to a stoichiometry of *33% at Tyr 138, whereas the full-length kinase inactive K297M mutant was phosphorylated to 510% ( Figure 5 and data not shown). Following phosphorylation, DI296T was tested for SH3 domain peptide ligand binding ability. The ligands used in the c-Src SH3 domain binding experiments were two high anity proline-rich peptides 12 residues in length and a control peptide 10 residues in length. All three were covalently coupled via an N-terminal linkage to AminoLink agarose (Pierce) at *10 mg ml. The two Figure 4b were excised, eluted, pooled, precipitated, and digested to completion with trypsin. The samples were then digested with thermolysin. Phosphopeptides were solubilized in pH 4.72 electrophoresis buer and spotted on thin layer cellulose (TLC) plates. Arrowheads indicate the origins. The phosphopeptides were resolved in two dimensions: pH 4.72 electrophoresis (pH 4.72e) horizontally (anode on the left) followed by ascending solvent chromatography in phospho-chromatography (P-Chromo) buer in the second vertical dimension as described in Materials and methods. Dried plates were exposed to ®lm overnight at 7708C with intensifying screens. binding peptide ligands, L14 (QSRPLPSPPKFT) and L35 (TPAPPPLPPRNV), were both derived from novel l cDNA expression library clones selected on the basis of the ability of the cDNA product to bind with high anity to the c-Src SH3 domain (Y Ivashchenko, personal communication). The control peptide (MPPPLPPVPP) was derived from 3BP-1, which binds to the Abl SH3 domain (Cicchetti et al., 1992) . In a control experiment to examine the SH3 domain speci®city of the DI296T cSrc fragment, we found as expected that both L14 and L35 peptide resins (Figure 8, lanes 1 and 2) bound soluble, immunoanity puri®ed DI296T c-Src as detected by immunoblotting with MAb 2-17, whereas, the control peptide (lane 3) did not. There was a slight preference for the L35 peptide ligand over the L14 peptide ligand. This may be due to the fact that L14 contains a lysine at position 10 that may cause steric hinderance to SH3 domain binding, since this residue can also be covalently coupled to the AminoLink agarose (i.e. the density of the N-terminally linked L14 peptide is lower than that for L35).
Following phosphorylation of DI296T by the PDGF receptor, the 32 PTyr 138 DI296T c-Src remained associated with the activated PDGF receptor. Therefore, to examine the eect of Tyr 138 phosphorylation on c-Src SH3 domain L14 and L35 peptide ligand binding, we had to develop a method to elute it from the receptor. Assuming that the interaction is SH2 mediated, we tested whether a synthetic phosphotyrosine-containing peptide corresponding to the human PDGFb receptor c-Src binding site (PTyr 579/ PTyr 581) could compete o the bound DI296T. However, we only achieved poor elution of 32 PTyr 138 DI296T c-Src from the receptor, even at 3 mM peptide, the highest concentration tested (data not shown). Assuming that the DI296T c-Src SH2 domain might be interacting with the receptor through in vitro autophosphorylation sites other than the identi®ed in vivo c-Src binding site, the ability of free PTyr to compete with the interaction was examined. At 25 ± 50 mM free PTyr, 32 P-phosphorylated Tyr 138 DI296T c-Src was eectively eluted from the activated PDGF receptor immune complex. Unfortunately, a small fraction of the 32 P-labeled immune-complexed PDGF receptor co-eluted with the 32 P-DI296T c-Src. This led to some non-speci®c background binding in the SH3 binding experiments.
As a control for the eects of taking DI296T through a phosphorylation reaction, we phosphorylated DI296T to a 25% stoichiometry with cyclin B/Cdc2, which phosphorylates c-Src at Thr 36 and Ser 74 (Thr 34 and Ser 72 in chicken c-Src) in the unique region of the c-Src N-terminus, and therefore should not interfere with the SH3 domain binding ability directly (Shenoy et al., 1989) .
32
PTyr 138 DI296T c-Src (Figure 9a ) and Cdc2-phosphorylated 32 P-DI296T c-Src (Figure 9b ) were bound to c-Src SH3 L35 peptide ligand resin. DI296T was detected both by autoradiography (Figure 9a Estimation of the quantity of DI296T c-Src in each sample was done visually using standard amounts of puri®ed DI296T c-Src on the alkaline phosphatase MAb 2-17 immunoblots (data not shown).
Consistently, Tyr 138 phosphorylation on DI296T cSrc diminished binding to L35, while Thr 36 and Ser 74 phosphorylation did not. Thus, the majority (490%) of the 32 P in PDGF receptor-phosphorylated DI296T failed to bind (Figure 9a ), whereas a signi®cant amount (*68%) of the total DI296T bound (data not shown). In contrast, the majority (*65%) of the 32 P in the Cdc2-phosphorylated DI296T bound (Figure 9b ). Only *50% of the total Cdc2-phosphorylated DI296T sample bound (data not shown), but this is likely to be because the DI296T c-Src was immunoanity puri®ed, and eluted under denaturing conditions. Some of the denatured molecules in the preparation could be substrates for cyclin B/Cdc2 but lack SH3 function, thus accounting for the 35% of the 32 P that did not bind. The problem with denatured DI296T molecules was not an issue with the PDGF receptor-phosphorylated material, since only native molecules with functional SH2 domains would bind to the receptor and be phosphorylated. In this single pass experiment the presence of co-eluted PDGF receptor (indicated in Figure 9a ) resulted in non-speci®c L35 binding, since the PDGF receptor was found to bind nonspeci®cally to all resins. However, despite this potential complication, *30% of the total DI296T failed to bind, which is close to the stoichiometry of phosphorylation.
We also tested the eect of Tyr 138 phosphorylation on binding of DI296T to L14 peptide resin. In this experiment Tyr 138 phosphorylated 32 P-DI296T c-Src was passed serially over two L14 peptide resin samples and the second supernatant was found to have *80% of the 32 P and *35% of the total DI296T Src protein (data not shown), which is also consistent with the stoichiometry of Tyr 138 phosphorylation. Based on the dierence in the binding ability of The N-terminal c-Src 298 residue fragment, DI296T, was bound to L14 (lane 1) and L35 (lane 2) SH3 peptide ligands coupled to agarose, as described in Materials and methods. Soluble DI296T c-Src was incubated with the speci®ed peptide resin followed by washing. After elution samples were resolved by 10% SDS ± PAGE followed by electrophoretic transfer to Immobilon (Millipore). Lane 3: Soluble DI296T c-Src was incubated with 3BP-1 peptide ligand as a negative control. Tyr 138 c-Src phosphorylation appears to be a PDGF receptor-speci®c event. Under no other circumstances tested was this same phosphorylation observed, although it is likely that the CSF-1 receptor, and perhaps other RPTKs that bind c-Src, are also capable of c-Src Tyr 138 phosphorylation upon association Roche et al., 1995) . Association of c-Src withthe nonreceptor PTK, FAK, did not result in Tyr 138 phosphorylation in coimmuno-precipitation kinase assays (data not shown). Thus, even another associated PTK is incapable of this phosphorylation. The only other c-Src N-terminal tyrosine phosphorylation site identi®ed is Tyr 92 (Tyr 90 in chicken c-Src), also in the SH3 domain. This site was identi®ed in polyoma mT-associated c-Src immune complex kinase assays (J Brugge, personal communication), and in c-Src immune complex kinase assays where a c-Src C-terminal antibody was used to precipitate c-Src from NIH3T3 cells (data not shown).
Phosphorylation of c-Src Tyr 138 in vitro appears to require direct association with the activated PDGF receptor via the SH2 domain. Although we did not test a c-Src SH2 domain binding mutant to provide formal proof, Tyr 138 phosphorylation of c-Src by the PDGF receptor and c-Src association were dependent on prior activation of the receptor in vitro and only Src constructs containing an SH2 domain were phosphorylated by the PDGF receptor at Tyr 138. Moreover, a bacterial c-Src GST-SH3 protein was not a substrate for the PDGF receptor (data not shown). Others have previously reported that the SH2 domain of Fyn is required for association of Fyn with the activated PDGF receptor and for PDGF-induced Fyn Nterminal tyrosine phosphorylation in vivo (Twamley et al., 1992) . It has been shown that Tyr 28 in the unique region of Fyn is a PDGF-induced site of N-terminal tyrosine phosphorylation (C Heldin, personal communication), so it is not clear that Src family PDGFinduced SH3 domain tyrosine phosphorylation is a general phenomenon.
A recent study by Stover et al. (1996) reports that Tyr 213 in the c-Src SH2 domain is phosphorylated by the PDGF receptor in vitro and in vivo. The discrepancies between their results and ours may be explained in part by dierent experimental approaches. First, Stover et al. (1996) made use of a Src PTK inhibitor in their kinase assays to avoid c-Src autophosphorylation, whereas we have used kinaseinactive point mutants or an N-terminal fragment. Second, a complex between c-Src and the receptor was not formed before the in vitro kinase assay, which may be a critical dierence, since Tyr 213 is likely to be masked when the SH2 domain is bound to a PTyrcontaining target protein. Third, direct comparison of in vivo mapping data are not possible since the mapping protocols were dierent. Furthermore, the original in vivo V8 mapping analysis by Gould and Hunter (1988) reported that the PDGF-induced PTyr was contained in N-terminal V3 and V4 fragments, which do not contain Tyr 213. Finally, in our studies a PSer/Thr DI296T c-Src remaining after incubation with L35-agarose. Quantitation of the 32 P signal was done on a 20 h phosphorimager exposure single point mutation, Tyr 138 to Phe, was found to eliminate the PDGF-induced N-terminal tyrosine phosphorylation in vivo, whereas Stover et al. (1996) did not test whether mutation of Tyr 213 eliminated PDGF-induced N-terminal tyrosine phosphorylation in vivo. From another perspective, the inhibitory eect of PDGF receptor phosphorylation on DI296T c-Src (which contains Tyr 213) SH3 domain binding ability in vitro also supports the identi®cation of Tyr 138 as a phosphorylation site. Nevertheless, the biochemical data reported by Stover et al. (1996) showing in vitro phosphorylation of Tyr 213 are compelling, and we cannot rule out that other sites of N-terminal tyrosine phosphorylation exist in c-Src. However, based on our evidence, only Tyr 138 appears to be phosphorylated in vitro when c-Src is in a complex with the PDGF receptor, and, more signi®cantly, in vivo in response to PDGF.
In addition to binding of the SH2 domain to the PDGF receptor, which may put Tyr 138 in the proper orientation to be phosphorylated, the correct secondary and tertiary structures of the c-Src PDGF-stimulated activation of all three proteins was detected when c-Src was isolated from either RIPA or 1% NP40 buer lysates; however, association of wild type c-Src with the PDGF receptor was only detectable in NP40 lysates. The presence of the wild type c-Src-associated PDGF receptor (Figure 6 ), actually resulted in less enolase phosphorylation than in the untreated samples. We believe this may be a consequence of c-Src substrate competition in the assay, since the same experiment performed using RIPA lysates resulted in greater enolase phosphorylation in the PDGF-treated wild type c-Src sample compared to the untreated sample (data not shown). This result implies that the PDGF receptor is a substrate for c-Src in vitro.
How does PDGF treatment activate c-Src? Current models of c-Src activation which are not mutually exclusive include: (1) dephosphorylation at Tyr 527 (chicken c-Src numbering), (2) binding of the c-Src SH2 domain to another PTyr-containing protein displacing PTyr 527 and relieving a repressed conformation (allosteric eect),and (3) phosphorylation at the autophosphorylation site, Tyr 416, by another PTK. In the case of the activated PDGF receptor and associated c-Src, all three could play a part in activating c-Src. The PTP SHP2 is associated with the activated PDGF receptor and could act to dephosphorylate Tyr 527 (Kazlauskas et al., 1993; Lechleider et al., 1993; Peng and Cartwright, 1995) . The fact that c-Src isolated from PDGF-treated cells lysed in RIPA buer, where the PDGF receptor does not remain associated, has increased activity potentially indicates that it is dephosphorylated at PTyr 527. The failure of both Y133F and Y138F c-Src SH3 mutants to remain associated with the PDGF receptor following activation even in NP40 lysates is also consistent with stable activation by PTyr 527 dephosphorylation. The binding site for c-Src on the activated PDGF receptor, doubly phosphorylated PTyr 579/PTyr 581 (Mori et al., 1993) , is a high anity c-Src SH2 binding site that could compete with c-Src C-terminal PTyr 527-Nterminal SH2 intramolecular binding and result in allosteric activation, and it would also expose PTyr 527 for PTP dephosphorylation. The anity of the c-Src SH2 interaction for a C-terminal PTyr 527 peptide is estimated to be several orders of magnitude less than for the high anity PTyr.Glu.Glu.Ile peptide (Bibbins et al., 1993; Liu et al., 1993a) . Since the kinase-inactive K297M c-Src mutant is extensively phosphorylated on Tyr 418 (416 in chicken c-Src) by the associated PDGF receptor in vitro (see Figure 2) , there is also a potential contribution to the activation of c-Src by this phosphorylation as well. This third possibility is intriguing and needs to be explored in a system such as this. Finally, CSK rephosphorylation of Tyr 527 could be negatively aected by phosphorylation at Tyr 138. To help elucidate which mechanism(s) is responsible, phosphopeptide mapping of the PDGF receptor-bound c-Src is necessary.
Since Tyr 138 is located in the c-Src SH3 domain binding groove and is known to contact the peptide ligand, the eect of Tyr 138 phosphorylation on SH3 peptide ligand binding ability was examined. A computer modeling exercise demonstrated that the negative electrostatic potential of the c-Src SH3 domain binding surface would be increased significantly by this phosphorylation. This suggests a potential mechanism for regulating c-Src SH3 domain ligand binding. An experimental determination of the eect of Tyr 138 phosphorylation on c-Src SH3 domain peptide ligand binding function was carried out with a PDGF receptor phosphorylated N-terminal 298 residue c-Src fragment, DI296T. Following elution from the PDGF receptor, Tyr 138 phosphorylated DI296T showed decreased binding to two c-Src SH3 domain peptide ligands immobilized on resin. We estimate this to be tenfold, but this could be higher, given the sources of error in our estimate (see Results).
SH3 binding was consistently diminished by Tyr 138 phosphorylation. Based on computer modeling studies phosphorylation at Tyr 138 in the c-Src SH3 domain would be predicted to interfere with interactions made by the peptide backbone of the ligand near one of the prolines. Since the L14 and L35 peptide ligands we used are predicted to bind to the c-Src SH3 domain in opposite orientations according to the recent models of Feng et al. (1994) and others (Lim et al., 1994) , we deduce that both ligand binding orientations are aected by Tyr 138 phosphorylation.
Involvement of the c-Src SH3 domain in signal transduction by the PDGF receptor The fact that the binding of the Y133F and Y138F mutant c-Src to the PDGF receptor is not stable in vivo might suggest that the c-Src SH3 domain is needed for binding to the PDGF receptor. However, when association with the activated receptor was tested in vitro the eciency of binding of puri®ed baculovirus-expressed Y133F and Y138F c-Src proteins was the same as that of wild type c-Src (data not shown). Why is there a dierence? Does coimmunoprecipitation accurately re¯ect this association in vivo? How does the Y133F c-Src mutant become phosphorylated at Tyr 138 in vivo if the PDGF receptor cannot associate with this mutant? The most likely possibility is that the stability of the association is reduced by these mutations leading to dissociation following lysis at low protein concentrations. Since there is no clear c-Src SH3 binding motif in the PDGF receptor, the SH3 domain may act to stabilize the active SH2 domain conformation, as is the case for the repressed conformation of c-Src, where stable SH2 domain binding to PTyr 527 requires the SH3 domain (Murphy et al., 1993; Okada et al., 1993; Superti-Furga et al., 1993) .
Since there is no role for Tyr 138 phosphorylation in c-Src activation, we have tested whether there is a role for Tyr 138 phosphorylation in PDGF and EGF mitogenic signal transduction. Src family kinases are required for PDGF, CSF-1, and EGF mitogenic signaling; and kinase-inactive Src and Fyn act as dominant negative inhibitors, with the inhibition of PDGF mitogenic signaling by the kinase-inactive Fyn mutant being SH2-dependent (Roche et al., 1995; Twamley-Stein et al., 1993) . Our data indicate that both the Y133F and Y138F c-Src mutants are dominant negative inhibitors of PDGF-and EGFstimulated DNA synthesis (Broome and Hunter, 1996) . Although this makes it impossible to determine whether Tyr 138 phosphorylation has a role in PDGF mitogenic signal transduction, we conclude that the SH3 domain has important function(s) independent of Src catalytic activity. An SH2-inactivating mutation (R177S) in each of the Y133F and Y138F mutant SH2 domains abolishes their dominant negative activity providing further evidence that these mutants do indeed associate with the PDGF receptor in vivo via their SH2 domains (Broome and Hunter, 1996; Erpel et al., 1996) .
Although we have been unable to de®ne a role for Tyr 138 phosphorylation, the location of this tyrosine on the SH3 domain binding surface suggests that phosphorylation could be involved in regulating SH3-mediated interactions ± both intra-and intermolecular. A recent report claims that Src becomes a soluble cytoplasmic protein following PDGF treatment (Walker et al., 1993) , but there is no evidence to suggest that c-Src leaves the receptor upon association. However, phosphorylation of Tyr 138 could lead to release of c-Src from the receptor. The fact that SH3 domain function is required for PDGF mitogenesis indicates that it may bind target proteins needed to initiate downstream signaling. The phosphorylation of Tyr 138 would disrupt the binding of ligands with the PXXP consensus based on our data, but it is possible that the phosphorylated SH3 could bind to novel ligands. Another non-receptor PTK found in hematopoietic cells, Btk, has recently been shown to become tyrosine phosphorylated within its SH3 domain at residue 223 (Park et al., 1996) . Interestingly, the equivalent tyrosine residue in c-Src is tyrosine 92, which as mentioned above is phosphorylated under certain circumstances. This residue is also located on the ligand binding surface and may function to regulate Btk SH3 ligand interactions.
Recent eorts to identify Src SH3 targets have resulted in the cloning of at least one good binding protein, Clone 10a (Alexandropoulos et al., 1995) , which proves to be part of the Cas-related protein Efs/ Sin (Ishino et al., 1995; Alexandropoulos and Baltimore, 1996) . The characterization of proteins in NIH3T3 cell lysates that bind to the Src, Fyn and Lyn SH3 domains in vitro has led to the identi®cation of p85a, Shc, Ras GAP, SAM68, paxillin, heterogeneous nuclear ribonucleoprotein K and other proteins as ligands (Fumagalli et al., 1994; Liu et al., 1993b; Pleiman et al., 1994; Taylor and Shalloway, 1994; Weng et al., 1993 Weng et al., , 1994 . However, until more is known regarding the physiological targets of SH3 domains, the biological signi®cance of Tyr 138 phosphorylation cannot be ascribed.
Materials and methods
In vitro mutagenesis and subcloning A 1.8 kb mouse neuronal c-Src cDNA (Martinez et al., 1987) was cloned into the BamHI site of M13mp18. Single strand DNA template was made and the neuronal insert of six amino acids was removed by deletion of the corresponding 18 nucleotides using a 24-mer mutagenic oligonucleotide CCAGTCTCCCTC/CGTGTTATTGAC synthesized on a Biosearch 8750 DNA synthesizer and the Amersham oligonucleotide-directed mutagenesis kit (#1523). This deleted construct, equivalent to wild type mouse c-Src, was then used as a template for further mutagenesis. Additional mutations were made singly and in combination using either the Amersham kit or by the Dut/Ung method (BIORAD) (Kunkel et al., 1987) . Amino terminal tyrosines 92, 94, 133, 138 and 151 were mutated to phenylalanine using CATAGTCAAAGAGGGCC, GT-GACTCAAAGTCATAG, TGGGGATGAAACCGGTC, GCGCCACAAAGTTGCTG, TTGCCAAAGAACCACT-CC mutagenic oligonucleotides respectively. Lys 297 involved in ATP binding in the catalytic domain was mutated to methionine using the mutagenic oligonucleotide CTTCAGAGTCATGATGGCAAC. The N-terminal 298 residue c-Src fragment, DI296T, consists of the ®rst 298 residues of wild type mouse c-Src with the single point mutation, I296T. The construct encoding this protein was obtained by accident during an attempt to produce the kinase-inactive K297R/M mutation. A frame shift was introduced resulting in a stop codon insertion at residue position 299. Mutations were con®rmed by dideoxy sequencing using Sequenase (USB) and the mutant inserts were then cloned from the M13 RF into pGEM4 (Promega) using the¯anking BamHI sites. Constructs were also subcloned into the baculovirus transfer vector pVL941 (Pharmingen) and the mammalian retrovirus expression vector pNeoMSV (a generous gift of J Karn) carrying a G418 resistance selectable marker (Karn et al., 1989) . Orientation was checked by using an internal SacI site in the c-Src cDNA.
Sf9 cell culture and baculovirus infection
Spodoptera frugiperda Sf9 cells were maintained in 16TNM-FH supplemented with 10% fetal calf-serum (King and Possee, 1992; Summers and Smith, 1987) . Cells were cultured and infected in suspension at densities recommended by Summers and Smith (1987) . Recombinant baculoviruses encoding wild type and Src mutants were generated by cotransfection of Sf9 cell monolayers with either an intact or deleted baculovirus AcMNPV genome (Pharmingen Baculogold #21000K) and the transfer vectors containing the src cDNA. Recombinant viruses were visually screened by plaque assay and expression was checked by kinase assay. A time course of expression and multiplicity of infection (MOI) were determined for optimal Src expression. One ± 10610 8 Sf9 cells were typically infected with an MOI of 5 : 1 and grown in suspension at a density of 1610 6 /ml. Infected cells were harvested 60 ± 72 h post-infection by centrifugation at 600 g followed by washing 16 in cold TD buer (25 mM Tris-Cl pH 7.5, 0.7 mM Na 2 HPO 4 , 5 mM KCl, 136.8 mM NaCl) plus 1 mM phenylmethyl sulfonyl¯uoride (PMSF). Infected cells were then lysed for protein or stored as frozen pellets at 7708C. These conditions are optimal for Src kinase activity in the baculovirus heterologous protein expression system. A recombinant baculovirus encoding the mouse PDGFb receptor (Morrison et al., 1989) was used as a means to generate activated PDGF receptor for the in vitro mapping studies. Infection conditions and harvesting procedures were the same as those for the Src baculoviruses.
Cell culture and radiolabeling
Primary mouse embryo ®broblasts lacking c-Src, a generous gift from J Brugge and T Thomas, were obtained from transgenic Src knockout mice (Thomas et al., 1991) and immortalized by infection with a SV40 large T expressing retroviral vector carrying a G418 resistance selectable marker gene, ZIPTEX (Brown et al., 1986) . Cells were maintained in Dulbecco modi®ed Eagle medium (DMEM) supplemented with 10% fetal calf serum. Wild type (wt) and mutant mouse c-Src retrovirus expression constructs were used to generate C2 retrovirus producing cell lines (Mann et al., 1983) by calcium phosphate transfection (Chen and Okayama, 1987) followed by G418 selection (Geneticin, Gibco-BRL #1811-031). Pools of resistant C2 colonies were made for each cell line and propagated in DMEM supplemented with 10% calf serum plus 400 mg/ml G418. C2 retroviral supernatants (10 ml DMEM/10% FCS) were harvested after 24 ± 36 h from 30 ± 40% con¯uent 10 cm plates and centrifuged for 10 min at 650 g. Polybrene was added to the cleared supernatants to 2 mg/ml. Six cm dishes of Src 7 cells were infected at 20 ± 30% con¯uence with the 10 ml C2 supernatants for 24 h followed by selection with 600 mg/ml G418 in DMEM plus 10% FCS. Stably expressing cell lines were then serumstarved at *80% con¯uence in DMEM/0.5% FCS for 24 ± 36 h and cells were either further incubated or labeled for 12 ± 14 h with 5 mCi [
32 P]orthophosphate (ICN) in 2.2 ml DMEM lacking phosphate plus 5% complete medium, 0.5% dialysed FCS also lacking phosphate, and 10 mM HEPES-OH pH 7.4. Labeled cells were treated with 50 ng/ ml PDGF BB (Amgen) for 5 min at 378C followed by removal of the labeling medium and washing with 2 ml TD at 48C.
Immunoprecipitation
Cells labeled metabolically with 32 P were lysed in 1 ml cold RIPA buer (10 mM sodium phosphate pH 7.0, 150 mM NaCl, 0.1% SDS, 1% Nonidet(NP)-40, 1% sodium deoxycholate, 2 mM EDTA, 50 mM NaF, 100 mM Na 3 VO 4 , 50 mM leupeptin (BACHEM), 1% Trasylol (Intergen), 1 mM dithiothreitol (DTT) and 1 mM PMSF) and clarified at 100 000 g for 30 min at 48C.
32 P-labeled pp60 c-Src was immunoprecipitated by using 5 ml of a 1 : 20 dilution of Mab 327 ascites (Lipsich et al., 1983) for 40 min on ice followed by a 20 min incubation on ice with 5 ml of anity-puri®ed rabbit anti-mouse immunoglobulin G (Cappel). Twenty-®ve ml protein A-agarose (Repligen) was added to the lysate followed by incubation at 48C for 1 h on a rotating wheel. Immunoprecipitates were washed three times with RIPA buer before the addition of 40 ml SDS ± PAGE sample buer. Unlabeled cells, including mouse Src 7 ®broblast cell lines expressing c-Src proteins and baculovirus-infected Sf9 cells, were lysed in 1 ml cold 1% NP40 buer (20 mM HEPES-OH pH 7.4, 150 mM KCl, 2 mM EDTA, 1% NP40, 1% Trasylol, 50 mM leupeptin, 100 mM Na 3 VO 4 , 1 mM DTT, and 1 mM PMSF) and clari®ed at 15 000 g for 10 min at 48C. pp60
c-Src and c-Src mutants were immunoprecipitated using 30 ml MAb 2-17 cell supernatant (Quality Biotech #LA074) for 40 min on ice followed by a 60 min incubation at 48C with 30 ml protein A-agarose (Repligen) on a rotating wheel. Immunoprecipitates were washed three times with 1% NP40 buer before the addition of 40 ml SDS ± PAGE sample buer or prepared for kinase assay.
In vitro PDGF receptor Src association and kinase assays Baculovirus-expressed mouse PDGF b receptor was immunoprecipitated from *5610 6 infected Sf9 cells lysed in 1 ml NP40 buer (above). Lysates were cleared by centrifugation at 15 000 g for 10 min at 48C and transferred to a new tube containing polyclonal anti-PDGF receptor antibody (5 ± 10 ml UBI #06-131 antipeptide/Sara Courtneidge, or 30 ± 50 ml Oncogene Science #PC17) and incubated on ice for 1 h. Twenty-®ve ml protein A-agarose (Repligen) was added and the incubation was continued for 1 h at 48C on a rotating wheel. Immunoprecipitates were washed 36 in 0.1% NP40 buer containing 20 mM HEPES-OH pH 7.4, 150 mM KCl, 2 mM EDTA, 500 mM Na 3 VO 4 and 1 mM DTT followed by one wash in 16 kinase buer without Mn 2+ or ATP (20 mM HEPES-OH pH 7.4, 1 mM DTT). Immune-complexed receptor was then autophosphorylated by in vitro kinase assay using 100 ml 16 kinase buer with 10 mM MnCl 2 and 100 mM ATP for 10 min at 308C. The activated receptor was then washed once with 16kinase buer without Mn 2+ or ATP and twice with 0.1% NP40 buer. Approximately 50 ± 100 ng of the speci®ed puri®ed, soluble baculovirus produced c-Src protein was added and incubated with the autophosphorylated receptor immunoprecipitate for 1 h at 48C on a rotating wheel. The PDGF receptor immunoprecipitate/associated c-Src protein complexes were then washed 36 in 0.1% NP40 buer followed by a wash in 16 kinase buer without Mn 2+ or ATP. Kinase reactions were then started by the addition of 25 ml 16 kinase buer with 10 mM MnCl 2 and 20 mCi [g 32 P]ATP (Amersham #AA0068; 3000 Ci/mmol). Reactions were stopped after 10 min at 308C by the addition of 25 ml 26SDS ± PAGE sample buer and boiled for 5 min. Reactions were analysed by resolution by 10% SDS ± PAGE. Preparative [ 32 P]Tyr 138 phosphorylation of the cSrc N-terminal fragment, DI296T c-Src, was done as described here for the receptor-associated c-Src mapping experiments except 10 mM unlabeled ATP was added to the second receptor-associated c-Src kinase assay. This was necessary to achieve maximal (*33%) phosphorylation at Tyr 138 of DI296T c-Src.
To detect baculovirus-expressed c-Src in the native puri®cation column fractions, kinase assays were done in a ®nal volume of 25 ml with 16 kinase buer containing either 10 mM Mg 2+ divalent cation (where speci®ed) and 10 mCi [g 32 P]ATP. Reactions were stopped after 10 min at 308C with 25 ml 26 sample buer and analysed as above. To assay for the speci®c activity of baculovirus-expressed c-Src proteins, 2 ml of sample was combined with 8 ml water and 10 ml of 26 kinase assay buer (40 mM HEPES-OH pH 7.4, 20 mM MgCl 2 or MnCl 2 where speci®ed, 20 mCi [g 32 P]ATP, 10 mM ATP and 2 mM DTT) containing 4 mg acid denatured enolase (Sigma) (3.5 mg/ml in 50 mM acetic acid incubated at 308C for 10 min) was added. The reaction was allowed to proceed for 2 min at 308C. The reaction was stopped by the addition of 20 ml 26 SDS ± PAGE sample buer, boiled for 5 min, and followed by 10% SDS ± PAGE analysis.
Peptide mapping and phosphoamino acid analysis
The upper hyperphosphorylated form of c-Src from in vivo 32 P-labeled Src immunoprecipitates was isolated by excision from un®xed dried gels for V8 and two-dimensional phosphopeptide mapping procedures. The baculovirusproduced c-Src proteins associated with and phosphorylated in vitro by the PDGF receptor were also isolated from un®xed dried gels for phosphopeptide mapping. All 32 Plabeled c-Src proteins were subjected to S aureus V8 partial proteolysis (Cleveland et al., 1977) and resolved by 15% SDS ± PAGE. Un®xed, dried gels were exposed to ®lm for autoradiography. For in vivo-labeled c-Src proteins from Src 7 ®broblasts, the gels were aligned with the ®lm and the cSrc V1 + , V3 + and V4 + N-terminal fragments were excised, eluted and the 32 P-labeled fragments were precipitated with TCA. The samples were subjected to trypsin followed by thermolysin double proteolysis using conditions described in Gould and Hunter (Gould and Hunter, 1988) and resolved in two dimensions on thin layer cellulose plates. The ®rst dimension was pH 4.72 electrophoresis (anode on the left) at 1 kV for 25 min followed by perpendicular second dimension thin layer ascending solvent chromatography in phosphochromatography buer (*12 h) (Boyle et al., 1991) .
For in vitro-labeled c-Src proteins from PDGF receptorassociated kinse assays, the gels were aligned with the ®lm and the c-Src V1, V3 and V4 N-terminal fragments were excised, eluted, and the 32 P-labeled fragments were precipitated with TCA. The samples were subjected to three combinations of proteases for two-dimensional phosphopeptide mapping as speci®ed in the ®gure legends: (1) trypsin followed by thermolysin double proteolysis as above; (2) trypsin, thermolysin, and proline-speci®c endopeptidase (ICN#320821) triple proteolysis; and (3) endoproteinase Asp-N (BMB#1054 589) followed by proline-speci®c endopeptidase double proteolysis. All secondary cleavages and the manual Edman degradation were carried out according to Boyle et al. (1991) . Resolution on thin layer cellulose plates was as described above for the in vivo samples except for the manual Edman degradation samples which were resolved in one dimension only at pH 3.5 electrophoresis (anode on the left) at 1 kV for 25 min.
In vitro c-Src kinase assays
To measure c-Src activation in quiescent Src 7 cells expressing wild type c-Src, Y133F c-Src, and Y138F c-Src treated with PDGF, in vitro c-Src immune complex kinase assays were performed using enolase as an exogenous substrate essentially as described in Gould and Hunter (1988) with the following modi®cations. Unlabeled cells were serum starved in 0.5% FCS/DMEM for 36 h then treated with 100 ng/ml PDGF BB for 30 min at 48C followed by washing with 2 ml TD at 48C. Lysates and c-Src immunoprecipitates were prepared as described above. In vitro kinase reactions were done in a 20 ml volume containing 16 kinase buer, 20 mCi [g 32 P]ATP, 2 mM unlabeled ATP and 4 mg acid denatured enolase. Reactions were stopped after 2 min at 308C by the addition of 20 ml 26 sample buer and analysed by 10% SDS ± PAGE and the 32 P signal was measured in the enolase bands. Levels of immunoprecipitated c-Src proteins were normalized by parallel immunoblotting half of each immunoprecipitate. The bound c-Src was detected as described below with 
c-Src immunoblotting
Proteins resolved by SDS ± PAGE were transferred to Immobilon-P PVDF membranes (Millipore) by semi-dry electrotransfer followed by blocking in 3% BSA in TBS (150 mM NaCl, 50 mM Tris-Cl pH 7.5) for 1 h room temperature (RT) or 14 h 48C. Blots were probed with a 1 : 1 (v/v) solution of MAb 2-17 hybridoma cell supernatant and TBST (TBS+0.05% Tween 20) for 1 h RT. The blots were washed three times for 5 min room temperature with TBST. Detection of bound MAb 2-17 was accomplished by three methods as speci®ed in each case: incubation with 1610 6 c.p.m./ml [ 125 I]protein A (ICN, 30 mCi/mg) in TBST, a 1 : 7000 dilution of sheep antimouse HRP (ECL) conjugate (Amersham) in TBST, or a 1 : 7000 dilution of rabbit anti-mouse alkaline phosphatase conjugate (Promega) in TBST for 1 h RT followed by washing as described above in TBST. [
125 I]protein A was detected by phosphorimaging or autoradiography. HRP was detected by autoradiography following ECL procedures (Amersham). Alkaline phosphatase was detected using a standard Promega protocol.
Computer modeling
Molecular modeling of the c-Src SH3 domain NMR solution structure from the protein database (Yu et al., 1992) was done using GRASP (Nicholls et al., 1991) and Midas Plus (Ferrin et al., 1988) software for imaging and manipulation respectively.
Phosphorylation of c-Src N-terminal fragment DI296T

Preparative [
32 P]phosphorylation of DI296T, the N-terminal fragment of c-Src (residues 1 ± 298) immunoanity puri®ed from baculovirus infected insect Sf9 cell lysates, was accomplished by two methods: (1) association with the activated PDGF receptor immunoprecipitate as described above to obtain Tyr 138 phosphorylation, and (2) with puri®ed GST-cyclin B/Cdc2 (a generous gift from N Watanabe) (Watanabe et al., 1995) from baculovirus coinfected insect Sf9 cells to obtain a Thr 36/Ser 74 phosphorylated control. The Tyr 138-phosphorylated [ 32 P]DI296Tc-Src was eluted from a preparative PDGF receptor immunoprecipitate/DI296Tc-Src complex kinase assay. Following two washes of the kinase assay with 0.1% NP40 buer, Tyr 138-phosphorylated [ 32 P]DI296Tc-Src was eluted by incubation at 48C for 45 min in 50 ml of elution buer containing 50 mM HEPES-OH pH 7.4, 1 mM EDTA, 500 mM Na 3 VO 4 , 1 mM DTT, 0.1% BSA, 150 mM KCl and 50 mM phosphotyrosine (PTyr). After elution, 15 ml was removed as an input control and combined with 40 ml 16 SDS ± PAGE sample buer, while the remainder was used in an SH3 binding experiment. For the Thr 36/ Ser 74 phosphorylated control, *5 ng GST-cyclin B/Cdc2 (1 ml) was used to phosphorylate *100 ng DI296Tc-Src (2 ml) in a 25 ml kinase reaction 10 min at 308C. The reaction buer contained 20 mM HEPES-OH pH 7.4, 1 mM DTT, 10 mM MgCl 2 , 10 mM ATP, and 20 mCi [g 32 P]ATP. Following the reaction, 8 ml was removed as an input control and combined with 42 ml 16SDS ± PAGE sample buer, while the remainder was used in an SH3 binding experiment.
c-Src SH3 peptide binding
Two peptides speci®c for the c-Src SH3 domain, L14 (QSRPLPSPPKFT) and L35 (TPAPPPLPPRNV) and a control peptide, (MPPPLPPVPP), were provided as a generous gift from Y Ivaschenko (RhoÃ ne-Poulenc Rorer, Collegeville, PA). The peptides were covalently coupled to AminoLink Agarose (Pierce#44890) and blocked with 3% BSA in TBS for 15 min RT followed by two washes with 20 mM HEPES-OH pH 7.4, 1 mM DTT, 1 mM EDTA and 0.1% BSA. Speci®city was con®rmed by incubation of 150 ng DI296Tc-Src with 25 ml L14, L35, and control peptide resins in 1 ml 0.1% NP40 buer, 0.1% BSA for 1 h at 48C on a rotating wheel. The resins were washed three times following binding: 16 with 0.1% NP40 buer, 16 with 750 mM LiCl in 0.1% NP40 buer and 16 with the same buer without salt. Washed resins were solubilized in 50 ml 16 SDS ± PAGE sample buer. The bound DI296T was detected by anti-Src/ECL immunoblotting following 10% SDS ± PAGE resolution and electrotransfer to Immobilon membranes. Eluted 32 Ptyr 138 DI296Tc-Src and soluble Ser 74/Thr 36 [ 32 P]DI296Tc-Src proteins were examined for their ability to bind to the L14 and L35 peptide resins using the same conditions as described for the speci®city control experiment except PTyr was added to 2 mM in the Thr 36/Ser 74 [ 32 P]DI296Tc-Src sample to match the PTyr concentration in the 32 PTyr DI296Tc-Src/ peptide binding samples. Following the adsorption step, supernatants were analysed for unbound DI296Tc-Src by immunoprecipitation with MAb 2-17 as described above with 50 ml MAb 2 ± 17 cell supernatant. Resin-bound DI296Tc-Src was analysed following washing, gel separation, and electrotransfer to Immobilon as described above except the 32 P signal was detected by autoradiography or phosphorimaging and the bound protein was detected by anti-Src/alkaline phosphatase immunoblotting. Quantitation of the 32 P signal was done with a phosphorimager. Immunoblot quantitation was done visually comparing standard amounts of DI296Tc-Src protein run in parallel.
Immunoanity puri®cation of c-Src from baculovirus-infected Sf9 cells
Immunoanity puri®cation using the Src-speci®c MAb 327 (Lipsich et al., 1983 ) was performed exactly as described by Morgan et al. (1991) . The N-terminal c-Src fragment, DI296T, was puri®ed from recombinant baculovirus infected Sf9 cell lysates using this procedure. Approximately 1610 8 infected Sf9 cells were harvested for protein puri®cation yielding *350 mg immunoanity-puri®ed DI296Tc-Src.
Native puri®cation of c-Src from baculovirus-infected Sf9 cells
(1) Membrane preparation Crude membranes were isolated from the infected Sf9 cells to enrich for membrane associated, and presumably properly myristoylated, c-Src. Approximately half of the total c-Src produced in baculovirus-infected Sf9 cells is insoluble and appears in the P100 fraction. Cells were allowed to swell 20 min on ice in *35 ml hypotonic lysis buer (see buers table) with 1 mM DTT and 1 mM PMSF added fresh. Cells were lysed with 30 strokes in a 15 ml type A dounce homogenizer (does not lyse nuclei) on ice. Nuclei were removed by centrifugation at 48C for 10 min at 650 g. The supernatant containing the crude membrane fraction was transferred to an SW28 (Beckman) Ultraclear centrifuge tube (#344058) and membranes were pelleted at 48C for 35 min at 27 000 r.p.m. (100 000 g). The membrane pellet was resuspended in 20 ml detergent containing solubilization buer by repeated pipetting on ice and brief vortexing before clari®cation by centrifugation at 48C for 20 min at 10 000 g (30 ml Corex tube). The supernatant can be applied directly to the anion exchange resin for chromatography or stored frozen at 7708C.
(2) Anion exchange chromatography All chromatography was carried out on a Pharmacia FPLC apparatus. Solubilized membranes were applied at 48C using a 10 ml superloop (Pharmacia FPLC) to a 1.6640 cm glass ccolumn (Pharmacia #19-5102-01) with adaptor (Pharmacia #19-5109-01) containing 20 ml Q Sepharose Fast Flow resin (Pharmacia #17-0510-01) equilibrated in column buer A. c-Src was eluted from the resin using a¯ow rate of 3 ml/min by the following: 15 min 0 mM NaCl; 10 min 100 mM NaCl; 5 min 150 mM NaCl; 10 min 150 ± 200 mM NaCl linear gradient; 5 min 200 mM NaCl; 10 min 200 ± 500 mM NaCl linear gradient followed by 15 min 500 mM NaCl. Fractions of 3 ml (or 1 min) were collected and c-Src was found to elute in fractions *35 ± 50 (*150 ± 250 mM NaCl) by kinase assay. The amount of each fraction used in the c-Src kinase assay described above was *10 ml. The divalent cation used in the Fast Q fraction cSrc kinase assays was Mg 2+ , since the phosphate buer interferes with the Mn 2+ kinase assay by causing precipitation of the Mn 2+ /[g 32 P]ATP complex.
(3) E 4 Y 1 anity chromatography The following procedure was adapted from E Racker (Zhang et al., 1991) . Pooled fractons 35 ± 50 from the anion exchange step were diluted 1 : 2 with column buer A and applied at 48C with a 10 ml superloop to a 1610 cm glass c-column (Pharmacia #19-5001-01) with adaptor (Pharmacia #19-5006-01) containing 5 ml E 4 Y 1 Sepharose 4B equilibrated in 100 mM NaCl column buer used in the anion exchange step. c-Src was eluted from the resin using ā ow rate of 1 ml/min by the following: 10 min 100 mM NaCl; 5 min 300 mM NaCl; 5 min 400 mM NaCl; 5 min 400 ± 500 mM NaCl linear gradient; 5 min 500 mM NaCl; 5 min 500 ± 600 mM NaCl linear gradient. Fractions of 1 ml (or 1 min) were collected and c-Src was found to elute in fractions *21 ± 35 (*300 ± 500 mM NaCl) by kinase assay as described above for the Fast Q step.
(4) Preparation of poly (Glu, Tyr) 4 : 1 (E 4 Y 1 ) Sepharose 4B 100 mg poly (Glu, Tyr) 4 : 1 (Sigma #P-0275) was coupled to 3 g CNBr-activated Sepharose 4B (Pharmacia #17-0430-01) according to the manufacturer's instructions. This yielded *12 ml of anity resin. The resin can be regenerated by washing at 1 ml/min two times with 0 M ± 1 M ± 0 M NaCl sawtooth linear gradients over 10 min and may be reused *®ve times.
(5) Comments on purity, storage, and handling pp60 c-Src obtained from the above two steps is *90% pure as measured by SDS ± PAGE silver staining with 90 and 50 kDa major but nonstoichiometric contaminating proteins (data not shown). Kinase activity is stable for 2 ± 3 weeks at 48C or several years at 7708C. Typical yield for 10 8 cells is *150 mg. Dialysis of the native c-Src preparation is necessary to remove protease inhibitors and phosphate buer which could interfere with the kinase activity when measured in a Mn 2+ -containing kinase reaction buer. Typically, a 100-fold dialysis is sucient.
(6) Buers: (a) Hypotonic lysis buer 10 mM triethanolamine (TEA), 9 mM K 2 HPO 4 , 1 mM KH 2 PO 4 , 100 mM Na 3 VO 4 , 5 mM EDTA, 1% Trasylol, 50 mM leupeptin, pH to 7.8 with HCl and ®lter. Add 1 mM DTT and 1 mM PMSF fresh.
(b)Solubilization buer Same as above hypotonic lysis buer with these changes: 1% Triton X100 (TX100) or 1% N-decyl maltoside (Calbiochem #252718) ± either detergent works but only N-decyl maltoside is dialysable. 10% glycerol, 1 mM EDTA.
(c) Column buers A and B Same as above hypotonic lysis buer with these changes: 0.1% detergent, 10% glycerol, 0.1 mM EDTA, 0.5 mM PMSF. B=buer A+1 M NaCl.
(d) Storage/dialysis buer (also may serve as column buer for additional steps), 20 mM TEA, 0.04% TX100 or N-decyl maltoside, 10% glycerol, pH to 7.8 with HCl and ®lter. Add 1 mM DTT fresh. Adjust NaCl to *150 mM for storage.
